Citation National Institute for Health and Clinical Excellence. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 201. 2010 Indexing Status Subject indexing assigned by CRD MeSH Anti-Allergic Agents; Antibodies, Monoclonal; Asthma; Childs Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence National Institute for Health and Clinical Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800; Fax: +44 020 7067 5801 Email: nice@nice.nhs.uk AccessionNumber 32011000065 Date abstract record published 26/01/2011 |